参考文献/References:
[1]Rizvi NA,Rusch V,Pao W,et al.Molecular characteristics predict clinical outcomes:prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene[J].Clin Cancer Res,2011,17(10):3500-3506. [2]Kris MG,Johnson BE,Berry LD,et al.Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs[J].Jama,2014,311(19):1998-2006. [3]Maruyama R,Nishiwaki Y,Tamura T,et al.Phase III study, V-15-32,of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer[J].J Clin Oncol,2008,26(26):4244-4252. [4]Lee DH,Park K,Kim JH,et al.Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy[J].Clinical Cancer Research,2010,16(4):1307-1314. [5]Kim ES, Hirsh V, Mok T,et al.Gefitinib versus docetaxel in previously treated non-small-cell lung cancer(INTEREST):a randomised phase III trial[J].Lancet,2008,372 (9652):1809-1818. [6]Kelly K,Azzoli CG,Zatloukal P,et al.Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer(NSCLC)after failure of prior platinum-based therapy[J].Journal of Thoracic Oncology,2012,7(6):1041-1048. [7]Ciuleanu T,Stelmakh L,Cicenas S,et al.Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced,non-small-cell lung cancer with poor prognosis(TITAN):a randomised multicentre,open-label,phase 3 study[J].Lancet Oncology,2012,13(3):300-308. [8]Maemondo M,Inoue A,Kobayashi K,et al.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J].New England Journal of Medicine,2010,362(25):2380. [9]Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or caboplatin-paclitaxel in non-small cell lung cancer[J].N Engl J Med,2009,361(10):947-957. [10]Zhou C,Wu YL,Chen G,et al.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL, CTONG-0802):a multicentre,open-label,randomised,phase 3 study[J].Lancet Oncology,2011,12(8):735. [11]Wu YL,Zhou C,Hu CP,et al.Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations(LUX-Lung 6):an open-label,randomised phase 3 trial[J].Lancet Oncology,2014,15(2):213-222. [12]Rosell R,Carcereny E,Gervais R,et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC):a multicentre,open-label,randomised phase 3 trial[J].Lancet Oncology,2012,13(3):239-246. [13]Mitsudomi T,Morita S,Yatabe Y,et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405):an open label,randomised phase 3 trial[J].Lancet Oncology,2010,11(2):121-128. [14]Fukuoka M,Wu YL,Thongprasert S,et al.Biomarker Analyses and Final Overall Survival Results From a Phase Ⅲ,Randomized,Open-Label,First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia(IPASS)[J].Journal of Clinical Oncology,2011,29(21):2866-2874. [15]Zhou C.Overall survival(OS)results from OPTIMAL (CTONG0802),a phase III trial of erlotinib(E)versus carboplatin plus gemcitabine(GC)as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer(NSCLC)[J].Journal of Clinical Oncology,2012,30(15_suppl). [16]Yun CH,Boggon TJ,Li Y,et al.Structures of lung cancer-derived EGFR mutants and inhibitor complexes:mechanism of activation and insights into differential inhibitor sensitivity[J].Cancer Cell,2007,11(3):217-227. [17]Chiu CH,Yang CT,Shih JY,et al.Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations[J].Journal of Thoracic Oncology,2015,10(5):793-799. [18]孟苗.埃克替尼治疗晚期非小细胞肺癌的疗效观察[J].中国实用医药,2016,11(20):166-167. [19]Mitsudomi T,Morita S,Yatabe Y,et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405):an open label,randomised phase 3 trial[J].Lancet Oncology,2010,11(2):121-128. [20]Pazares L,Soulières D,Moecks J,et al.Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC[J].Journal of Cellular&Molecular Medicine,2014,18(8):1519-1539. [21]Gridelli C,Ciardiello F,Feld R,et al.International multicenter randomized phaseⅢstudy of first-line erlotinib(E)followed by second-line cisplatin plus gemcitabine(CG)versus first-line CG followed by second-line E in advanced non-small cell lung cancer(aNSCLC):The TORCH trial.[J].Journal of Clinical Oncology,2010,28(15):7508. [22]Kim ES,Hirsh V,Mok T,et al.Gefitinib versus docetaxel in previously treated non-small-cell lung cancer(INTEREST):a randomised phase III trial[J].Lancet,2008,372(9652):1809.
相似文献/References:
[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Medical Information,2018,31(20):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Medical Information,2018,31(20):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的
表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Medical Information,2018,31(20):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Medical Information,2018,31(20):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2019,32(20):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[6]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Medical Information,2018,31(20):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[7]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2018,31(20):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[8]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Medical Information,2022,35(20):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[9]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Medical Information,2019,32(20):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
[10]孟凡亮,陈亚新,高建荣,等.血清Ang-2、VEGF、PCDGF在非小细胞肺癌中的诊断价值[J].医学信息,2019,32(15):66.[doi:10.3969/j.issn.1006-1959.2019.15.021]
MENG Fan-liang,CHEN Ya-xin,GAO Jian-rong,et al.Diagnostic Value of Serum Ang-2,VEGF and PCDGF in Non-small Cell Lung Cancer[J].Medical Information,2019,32(20):66.[doi:10.3969/j.issn.1006-1959.2019.15.021]